Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 17/20 | 0.86 |
| ▸ | CDK4 | P11802 | 16/20 | 0.86 |
| ▸ | GSK3B | P49841 | 11/20 | 0.72 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.70 |
| ▸ | CCNK | O75909 | 1/20 | 0.62 |
| ▸ | CCNC | P24863 | 1/20 | 0.62 |
| ▸ | CDK8 | P49336 | 1/20 | 0.62 |
| ▸ | CDK9 | P50750 | 1/20 | 0.62 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4487812 | 0.93 | CDK2 (1.00) | CDK2CDK4GSK3BDYRK1ACCNK | |
| SCHEMBL4479694 | 0.92 | CDK2 (0.77) | CDK2CDK4GSK3BDYRK1A | |
| SCHEMBL4475408 | 0.90 | CDK2 (1.00) | CDK2CDK4GSK3BDYRK1A | |
| SCHEMBL4482264 | 0.89 | CDK2 (0.73) | CDK2CDK4GSK3BDYRK1A | |
| SCHEMBL4473007 | 0.85 | CDK2 (1.00) | CDK2CDK4GSK3BDYRK1ACCNK | |
| SCHEMBL4488333 | 0.84 | CDK2 (1.00) | CDK2CDK4GSK3BDYRK1ACCNK | |
| SCHEMBL4480496 | 0.83 | CDK2 (1.00) | CDK2CDK4GSK3BDYRK1ACCNK | |
| SCHEMBL4484286 | 0.83 | CDK2 (1.00) | CDK2CDK4GSK3BDYRK1ACCNK | |
| SCHEMBL4475712 | 0.83 | CDK2 (1.00) | CDK2CDK4GSK3BDYRK1ACCNK | |
| SCHEMBL4483102 | 0.82 | CDK2 (0.81) | CDK2CDK4GSK3BDYRK1ACCNK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060069097-A1 | Pyradazine compounds as gsk-3 inhibitors | SMITHKLINE BEECHAM CORPORATION | 2006-03-30 | — | — | US | claimed |
| EP-1551842-A1 | PYRADAZINE COMPOUNDS AS GSK-3 INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-07-13 | — | — | EP | claimed |
| WO-2004035588-A1 | PYRADAZINE COMPOUNDS AS GSK-3 INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-04-29 | — | — | WO | claimed |
| US-7582630-B2 | Pyradazine compounds as GSK-3 inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-01 | — | — | US | disclosed |
| US-7582630-B2 | Pyradazine compounds as GSK-3 inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-01 | — | — | US | disclosed |
| US-7582630-B2 | Pyradazine compounds as GSK-3 inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-01 | — | — | US | disclosed |
| US-20060069097-A1 | Pyradazine compounds as gsk-3 inhibitors | SMITHKLINE BEECHAM CORPORATION | 2006-03-30 | — | — | US | disclosed |
| EP-1551842-A1 | PYRADAZINE COMPOUNDS AS GSK-3 INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-07-13 | — | — | EP | disclosed |
| WO-2004035588-A1 | PYRADAZINE COMPOUNDS AS GSK-3 INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-04-29 | — | — | WO | disclosed |
| WO-2004035588-A1 | PYRADAZINE COMPOUNDS AS GSK-3 INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069097-A1 | Pyradazine compounds as gsk-3 inhibitors | GSK3B, GSK3A, GSKIP | CDK2 91/4885CDK4 218/4885GSK3B 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.